WS #16232
Abbott Laboratories reported Q3 adjusted EPS of $1.42, in line with estimates, and revenue of $13.01B, slightly beating expectations. However, the company narrowed its full-year adjusted EPS guidance to $5.50-$5.55 from a previous range of $5.45-$5.60, citing soaring costs associated with recent acquisitions. This guidance cut suggests management is prioritizing margin protection over aggressive growth, which may temper investor enthusiasm despite the top-line beat.
Abbott Laboratories Guidance Narrowing
Abbott Laboratories reported Q3 adjusted EPS of $1.42, in line with estimates, and revenue of $13.01B, slightly beating expectations. However, the company narrowed its full-year adjusted EPS guidance to $5.50-$5.55 from a previous range of $5.45-$5.60, citing soaring costs associated with recent acquisitions. This guidance cut suggests management is prioritizing margin protection over aggressive growth, which may temper investor enthusiasm despite the top-line beat.